Immunotherapy : Episode 8

Video

Episode 8 - A Managed Care Approach to Immunotherapy

As the panelists discuss the skepticism often associated with treatment outcomes of immunotherapy when compared with outcomes of standard treatment options such as chemotherapy, the panelists conclude that tumor response (or reduction) should not be considered an ultimate end point when determining results.

In practice, Daniel J. George, MD, believes that patients’ goals are achieved when they can experience a decent quality of life without experiencing any disease progression. Dr George further explains that some patients that have tumor burden still experience a fantastic quality of life if their treatment side effects are managed correctly.

Jeffrey Weber, MD, PhD, agrees with Dr George and explains that although tumor response is a desirable end point, as recognized by the FDA, it should be perceived as a useful, but not ultimate, result factor.


Related Videos
Sandra Cuellar, PharmD
dr carol regueiro
dr carol regueiro
Screenshot of Adam Colborn, JD during an interview
dr carol regueiro
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with James Chambers, PhD
Corey McEwen, PharmD, MS
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo